Narek Shaverdian, MD
Radiation Oncologist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Request an Appointment
About Me
- Assistant Attending Radiation Oncologist
I am a radiation oncologist who specializes in caring for people with thoracic cancers, such as lung cancer, thymoma, and esophageal cancer. I also treat people with metastases to spine, bones, and other organs. I see patients at MSK Commack on Long Island.
Read more
I was drawn to being a cancer doctor and researcher because, as with so many families, mine too has been impacted by this disease. I strive to provide the same personalized care that I would hope someone in my own family would receive.
When I first meet patients, I help them understand the role radiation therapy can play in their specific treatment plan. Often patients may have new questions or challenges after we meet, so I want my patients to know that I strive to be completely accessible. I am committed to working through all the steps with them to ensure that they have the best treatment experience and best outcome. It is a great privilege to get to know my patients and their families and work to provide cutting-edge, personalized care.
There have been great advances in radiation oncology. These enable us to control and defeat cancer with minimal side effects. At Memorial Sloan Kettering, we take advantage of the most sophisticated image guidance technology to deliver radiation with great precision. We have developed ways to treat some people with fewer sessions by using higher, tightly focused doses. We are also investigating ways to combine radiation with certain drugs to get even better results.
I want patients to know that the care I provide is complemented by a large team of experts in oncology, surgery, radiology, and pathology, all who work closely with each other. I hope my patients always leave my office feeling informed, comfortable, and confident in their treatment plan.
A radiation oncologist is a cancer doctor with special training in using radiation therapy (RT) to treat cancer with radiation.
My Specialties
- Lung Cancer
- Spine Tumors
- Bone Tumors
- Esophageal Cancer
- Metastases
- Image-Guided Radiation Therapy (IGRT)
- Intensity-Modulated Radiation Therapy (IMRT)
- Stereotactic Radiosurgery (SRS)
- Stereotactic Body Radiation Therapy (SBRT)
- Stereotactic Ablative Radiotherapy (SABR)
Education
- MD, University of Wisconsin
Residencies
- Preliminary Medicine - University of Washington
- Radiation Oncology - University of California Los Angeles
Awards and Honors
- Radiological Society of North America (RSNA) Roentgen Research Award (2018)
- American Society for Radiation Oncology (ASTRO) Basic/Translational Science Abstract Award (2017)
- American Society for Clinical Oncology (ASCO) Merit Award (2017)
- American Medical Association (AMA) Foundation Seed Grant (2017)
- American College of Radiation Oncology (ACRO) Grant (2015)
- Alpha Omega Alpha Honor Medical Society (2013)
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Shaverdian sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
See all External Beam Radiotherapy Service, Regional Care Network doctors
Clinical Trials
- Clinical Trials Co-Investigated by Dr. Shaverdian
- A Phase II Study of Alectinib, Entrectinib, or Vemurafenib/Cobimetinib Therapy Before Surgery in Patients with Nonmetastatic Non-Small Cell Lung Cancer with Certain Molecular Changes
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Shaverdian N, Offin M, Shepherd AF, Simone CB 2nd, Gelblum DY, Wu AJ, Hellmann MD, Rimner A, Paik PK, Chaft JE, Gomez DR. The Impact of Durvalumab on Local-Regional Control in Stage III NSCLCs Treated With Chemoradiation and on KEAP1-NFE2L2-Mutant Tumors. J Thorac Oncol. 2021 Aug;16(8):1392-1402. doi: 10.1016/j.jtho.2021.04.019. Epub 2021 May 13. PMID: 33992811; PMCID: PMC8316395.
Shaverdian N, Gillespie EF, Cha E, Kim SY, Benvengo S, Chino F, Kang JJ, Li Y, Atkinson TM, Lee N, Washington CM, Cahlon O, Gomez DR. Impact of Telemedicine on Patient Satisfaction and Perceptions of Care Quality in Radiation Oncology. J Natl Compr Canc Netw. 2021 Jan 4;19(10):1174-1180. doi: 10.6004/jnccn.2020.7687. PMID: 33395627; PMCID: PMC8254817.
Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB, Lee P. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncology. 2017 Jul;18(7):895-903.
Read more
Shaverdian N, Veruttipong D, Wang J, Kupelian P, Steinberg M, Lee P. Pretreatment anemia portends poor survival and nonlocal disease progression in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy. Journal of Thoracic Oncology. 2016 Aug;11(8):1319-25.
Shaverdian N, Wang PC, Steinberg M, Lee P. The patient’s perspective on stereotactic body radiation therapy vs. surgery for the treatment of early stage non-small cell lung cancer. Lung Cancer. 2015 Nov;90(2):230-3.
Visit PubMed for a full listing of Dr. Shaverdian’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Narek Shaverdian discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
